MedTrace Logo

Evaluation of Effectiveness and Safety of Evolut R Valve In Patients With Pure Aortic Regurgitation

NCT03578952 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-02-22

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in severe 'pure Aortic regurgitation (AR)' using Evolut R valve (Medtronic, Minneapolis, MN).

Conditions

  • Aortic Valve
  • Aortic Valve Insufficiency
  • Aortic Regurgitation
  • Regurgitation, Aortic Valve
  • Aortic Incompetence

Interventions

DEVICE

TAVR with Evolut R valve

TAVR with Evolut R valve

Sponsors & Collaborators

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • Seung-Jung Park

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-10
Primary Completion
2019-02-21
Completion
2019-02-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03578952 on ClinicalTrials.gov